hotspot -WSS

hotspot

author：hotspot 2025-09-30 21:22:26 - browse：1

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： American taxpayers paid $1.8 trillion in health care costs in 2022

focus

WSS

A preacher's new calling: Diversifying neuroscience research

Secretariat’s lessons for human medicine

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Surprise medical billing ban raises prices elsewhere

A preacher's new calling: Diversifying neuroscience research

In shift, Texas to cover initial consult for Afghan baby's gene therapy

hotspot

hotspot

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Opioid cravings were reduced by anti

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Guidelines to prevent youth baseball injuries need more muscle

FDA warns medical device makers about rise in fabricated data

Sports medicine is finally prioritizing gender equality

At JPM 2024, hospital systems pitch financial strength to investors

explore

In 'major milestone,' FDA approves first cell therapy for solid tumors

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Medicare Advantage overpayments discussion gets experts fired up

Gene therapy denied for Afghan refugee whose father aided U.S.

MD Anderson's Padmanee Sharma responds to research credit suit

Gene therapy denied for Afghan refugee whose father aided U.S.

focus

Wikipedia

leisure time

hotspot